Get started

SAVA

Swing trading on SAVA - 17-10-2022Hello everyone, 🌟 Here again Romluck with a new trading idea, The trading ideas I find are after searching and investing time. Thanks for the like and comment. "Cassava Sciences" : NASDAQ:SAVA Market Cap 1.55B Short Float 28.49%⛔️ Target Price 50$💰 What i see :👀 🔆triggering a possible buy near $40.28. 🔅place to put a stop loss is, near $32.98. 🔆Based on the entry and stop-loss, the estimated risk for the trade is $7.3 per share ($40.28 - $32.98). ⚠️__🚧___🚧___🚧__🚧___🚧__🚧_🚧__🚧__🚧__🚧__🚧_🚧__🚧__🚧_🚧__🚧_⚠️ There is no recommendation for buying or selling or any action in the stock, I am not an investment advisor and publish this article as a hobby only. Everyone has to perform risk management on their own or contact an investment advisor with a license, I don't have one. Investing in the stock market involves risking your money!⛔️ have fun
NASDAQ:SAVALong
by ROMLUCK
2
Cassava Sciences losing momentum. SAVAWe are not in the business of getting every prediction right, no one ever does and that is not the aim of the game. The Fibonacci targets are highlighted in green with invalidation in red. Fibonacci goals, it is prudent to suggest, are nothing more than mere fractally evident and therefore statistically likely levels that the market will go to. Having said that, the market will always do what it wants and always has a mind of its own. Therefore, none of this is financial advice, so do your own research and rely only on your own analysis. Trading is a true one man sport. Good luck out there and stay safe
NASDAQ:SAVAShort
by Rykin_Capital
2
Sava Ready to Plunge? Cassava Sciences Short Term - We look to Sell at 32.45 (stop at 36.81) We look to sell rallies. Trading volume is increasing. Previous support, now becomes resistance at 32.00. We can see no technical reason for a change of trend. The bias is still for lower levels and we look for any gains to be limited. Our profit targets will be 12.45 and 7.56 Resistance: 32.00 / 40.00 / 60.00 Support: 23.00 / 11.00 / 5.00 Disclaimer – Saxo Bank Group. Please be reminded – you alone are responsible for your trading – both gains and losses. There is a very high degree of risk involved in trading. The technical analysis, like any and all indicators, strategies, columns, articles and other features accessible on/though this site (including those from Signal Centre) are for informational purposes only and should not be construed as investment advice by you. Such technical analysis are believed to be obtained from sources believed to be reliable, but not warrant their respective completeness or accuracy, or warrant any results from the use of the information. Your use of the technical analysis, as would also your use of any and all mentioned indicators, strategies, columns, articles and all other features, is entirely at your own risk and it is your sole responsibility to evaluate the accuracy, completeness and usefulness (including suitability) of the information. You should assess the risk of any trade with your financial adviser and make your own independent decision(s) regarding any tradable products which may be the subject matter of the technical analysis or any of the said indicators, strategies, columns, articles and all other features. Please also be reminded that if despite the above, any of the said technical analysis (or any of the said indicators, strategies, columns, articles and other features accessible on/through this site) is found to be advisory or a recommendation; and not merely informational in nature, the same is in any event provided with the intention of being for general circulation and availability only. As such it is not intended to and does not form part of any offer or recommendation directed at you specifically, or have any regard to the investment objectives, financial situation or needs of yourself or any other specific person. Before committing to a trade or investment therefore, please seek advice from a financial or other professional adviser regarding the suitability of the product for you and (where available) read the relevant product offer/description documents, including the risk disclosures. If you do not wish to seek such financial advice, please still exercise your mind and consider carefully whether the product is suitable for you because you alone remain responsible for your trading – both gains and losses.
NASDAQ:SAVAShort
by Saxo
Cassava Sciences Stock Is Worth Almost 4x MoreCassava Sciences Stock Is Worth Almost 4x More After Adjusting for Risk * 1/10/2022 1:45pm EST * By Mark R. Hake, CFA Cassava Sciences (NASDAQ:SAVA) stands to gain a good deal this year. This will all depend on the company’s Phase 3 clinical trials progress in the results on actual patients with Alzheimer’s disease. SAVA stock could become a major winner as a result, or potentially a loser. The upside will also be subject to how well the results are received both by the medical community and the market. As a result, SAVA stock is either going to be seen as a winner or a huge loser. There is probably not too much room in between. As one author pointed out recently, the market thinks there is only about a 6% chance that the company’s Alzheimer’s drug, Simufilam, will be successful. But if it is successful, the author believes there is a 66% chance that the stock could rise 11 times before the U.S. Food and Drug Administration (FDA) approves the drug for Alzheimer’s treatment. Where Things Stand With Cassava Sciences The trials conducted up until now involve “the distribution of 147,000 Simufilam to more than 250 Alzheimer’s patients in at least 16 investigator sites.” So far there have been no drug-related serious adverse events. However, these were open-label studies involving no placebos. The two Phase 3 clinical trials now underway involve a placebo and blind study. In fact, on page 17 of the company’s Jan. 2022 presentation on their website, it says: “Treatment effects observed in an open-label study are not proof of drug safety or efficacy, nor can open-label data predict clinical success in a Phase 3 program.” So, the company has been more or less compelled to proceed to a Phase 3 study in order to assure its efficacy. However, on page 23 of the slide deck, the company said that the FDA approved its Phase 3 protocol: “FDA agrees that the completed Phase 2 program, together with an upcoming and well-defined Phase 3 clinical program, are sufficient to show evidence of clinical efficacy.” So, you can see that if the Phase 3 trials go well, the FDA could well approve the drug for the treatment of Alzheimer’s disease. Therefore, in a way, it won’t matter what the market thinks about the results. The only issue is whether the FDA will approve the drug. And that alone will make the company. Where This Leaves Cassava Sciences I suspect that once the first study results come out for the Phase 3 trials the market will begin to focus on the mechanics of how the drug will get distributed once it is approved. The company’s Chief Executive Officer Remy Barbier has made it clear in interviews that the company will likely have to partner with a major drug manufacturer/distributor. This could lead to a revenue-sharing deal. What is even more interesting here is the possibility that the company could announce a royalty/revenue-sharing deal prior to any results for Phase 3. This could also act as a major catalyst for SAVA stock. I suspect that will happen some time late in the first quarter and/or in the second quarter. Expect to see analysts begin to project the company’s valuation based on this. So far, not many observers of the stock have put together cogent models with a major drug partner for Cassava Sciences. However, at today’s price, $47.95, the stock has a almost $2 billion market capitalization. There are no analyst forecasts for 2023 or beyond. This goes to show that everyone is virtually waiting on the edge of their seat for the results of the Phase 3 clinical trials. What To Do With SAVA Stock I am personally very positive on SAVA stock and indeed have a position in the company. In fact, now that the stock is down off of its highs, I intend to buy more of the stock. However, I freely admit that this is a highly speculative position to take. For example, as I pointed out above, there are no real estimates for the company’s earnings going forward. Moreover, there is no real assurance that the FDA will approve the drug as a treatment for Alzheimer’s. Here is a simple probability exercise that shows why I have taken a position. Analysts seem to believe that if the drug is approved, the stock will be worth 11 times its price today. That represents a 10 times gain. But if it is not approved and the trials are a bust, the stock could easily fall 80% to 90%. Let’s call it negative 95%. Now, let’s give the chance that it is going to be a success a one-third chance. That leaves a two-thirds chance it will bust. So, here is the expected return (ER). We multiply 10 x 0.333, and get an ER of 3.333 times. But the downside results in an ER of -63.37% (i.e., negative 95% x 0.6666). So, if we add the total ERs together, the total ER is still positive. In other words, SAVA stock is worth 3.7 times (i.e. 1 + 270% return) its price today, or $177.42. So, despite the risks, this looks like a pretty good risk-adjusted return on investment candidate.
NASDAQ:SAVALong
by binancash
#SAVA, rounded bottom, long biasA quick brief, Cassava Sciences, Inc. engages in the development of novel drugs. It focuses on developing product candidates intended for the treatment of Alzheimer's disease, including PTI-125 and PTI-125Dx. The company was founded by Remi Barbier and Barry M. Sherman in May 1998 and is headquartered in Austin, TX. Quick take on the price action for SAVA, the stock’s volatility has been largely based on the events surrounding Simufilam – the company’s prospective treatment for the difficult-to-treat Alzheimer’ disease (AD). Average Analyst rating for SAVA is a price target of USD 147. (CMP : 68.53) I am expecting to see some resistance around $76, which is also the 20 week Moving Average. This stock has given a great move over the last 3 days and is currently 24% away from the 5 day Moving Average, 34% away from the 20 Day Moving Average and about 25% away from the 200 Day Moving Average Given the formations on the chart, looks like a nice rounding bottom being formed on SAVA. There Is likelihood price will test the 76 dollars range soon. If it holds there, next target could be 96 dollars, else look for a move back towards the 20 Day Moving average I think this stock is great "buy the dip" stock and would be looking to accumulate Do note, this stock is extremely volatile, do your research.
NASDAQ:SAVALong
by LoveForCharts
4
Can SAVA get back to $100 in the short term? $SAVA (Cassava Sciences) saw an insane rally in 2021 from $7 to $145 on the hopes that its groundbreaking Alzheimer's treatment will yield promising results never before seen in the history of the disease. Currently there are no Alzheimer's modifying therapies on the market and if the data surrounding Cassava's main drug, simufilam, is accurate then it could be the first of its kind. SAVA saw a sell-the-news event when it announced its promising results, suffering a 23% drop on July 29. Soon thereafter a Stat News article was released criticizing Cassava's results, citing a group of independent researchers. The stock dropped a total of 55% from highs. Is this a buying opportunity? Obviously we are largely delving in uncharted territory and financial analysts/traders won't be able to infer whether the science is reliable or not. However, traders know how market cycles largely work. There is often a second wave of optimism after negative news coverage (whether a short report or a hit piece), driven by those who are willing to speculate. SAVA is showing a bullish harami on the 1D and it has dropped to the Fibonacci golden pocket level, also at the 100 MA where it has routinely found support. This could be a buying opportunity for those who are in the market for a bit of risk. As long as #SAVA is above the 100 MA, I'm willing to hold it in the mid term and will ride the next wave of positive financial/medical news. Entry: $79 SL: soft SL with manual monitoring if it breaches the 100 MA TP: $88, $94, $100
NASDAQ:SAVALong
by TheTravel1ngTrader
SAVA Stuck At 382It's interesting to see what happens after plotting out fib lines sometimes. SAVA , for instance...using the earlier lows and the recent high as anchors we can see that the 382 fib line has been a very clear area of both support and resistance almost to the exact mark. Sure 236 played this role before the Alzheimer's data but now SAVA has reset back to some familiar territory and, so far, is mimicking its trend before the big breakout, which is 382 fib resistance being an issue. Multiple times in the last few days, this area was tested and SAVA was rejected (including 8/3). BUT with the market seemingly building optimism, it could once again be an important area on the chart to be aware of. "The biotech industry is well known for volatility. When you’re talking about developing life-changing treatments, there’s a lot to account for. The phase trial process brings the potential for big progress but can also put the brakes on otherwise strong rallies in the market. We recently saw this with companies like Cassava Sciences (NASDAQ: SAVA) and Annovis Bio (NYSE: ANVS ), which were also former penny stocks. Both companies developing Alzheimer’s treatments revealed data that didn’t impress the market at all. In response, shares of both stocks plummeted." Quote Source & Read More: Hot Biotech Stocks To Watch After Sanofi’s Acquisition Of Translate Bio
NASDAQ:SAVA
by PennyStocks101